Goldman Sachs analyst Salveen Richter reiterated an Early-Stage Biotech rating on Apogee Therapeutics Inc (NASDAQ: APGE).The analyst comments "APGE reported ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE